SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.48+0.7%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (13729)6/1/2000 12:05:00 AM
From: aknahow  Read Replies (2) of 17367
 
Bluegreen, IMO a peer reviewed article is better for convincing others to support possible action. If we just get the numbers from what all agree was a complex trial it will be difficult to garner support.

It is possible that the U.K. may feel more of a need to approve Neuprex before the FDA considers it. Then again being a Socialist system, it really will probably be money that matters and they won't want an expensive drug. One thing to profess to care for the children and the poor and another to actually come up with the funds to do so.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News